PEG: Loss before tax narrowed to DKK -26.4 million amid clinical progress and ongoing funding efforts
阅读少于1分钟
Strategic and operational progress led to a reduced loss before tax of DKK -26.4 million, with no revenue recognized as clinical programs advanced. Liquidity was supported by convertible loans, while the Portinho S.A. receivable remains a key uncertainty.
Original document: Pharma Equity Group A/S Class A [PEG] Annual Report — Mar. 25 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr